Physician

Francis Patrick Matuszak, DO

According to 2025 Medicare claims, Francis Matuszak, DO (NPI: 1447755830) practices medical oncology in the Ocala, FL market, with the plurality of this provider's patient population coming from Marion, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34474-9673.

Matuszak's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 682 traditional Medicare patients, billed 77,770 HCPCS/CPT codes, and received $1,189,969 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 397 prescription claims across 87 beneficiaries totaling $1,423,855 in drug costs, led by Revlimid (Lenalidomide). Open Payments data shows 100 records totaling $2,543. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $14,159 to $1,423,855. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$595K$1.2M2024 Medicare payment: $1,189,969 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022N/RN/RN/R
2023N/RN/RN/R
202468277,770$1,189,969

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$712K$1.4M2018 Drug cost: $14,159 (USD; Tot_Drug_Cst)2019 Drug cost: $25,367 (USD; Tot_Drug_Cst)2021 Drug cost: $41,381 (USD; Tot_Drug_Cst)2022 Drug cost: $388,757 (USD; Tot_Drug_Cst)2023 Drug cost: $611,191 (USD; Tot_Drug_Cst)2024 Drug cost: $1,423,855 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
20181334$14,159
20193287$25,367
2020N/RN/RN/R
20211537$41,381
202229262$388,757
202323461$611,191
202487397$1,423,855

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more145162$70
J0897Injection, denosumab, 1 mg1197,980$21
96372Injection of drug or substance under skin or into muscle235345$11
36415Insertion of needle into vein for collection of blood sample402574$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count341532$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RevlimidLenalidomide26714$371,108
OpdivoNivolumab13364$185,942
HerceptinTrastuzumab14276$85,794
XgevaDenosumab20560$63,592
EliquisApixaban14480$9,234

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.100$2,543Novartis Pharmaceuticals Corporation
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Francis Patrick Matuszak, DO?

Tedicare shows public-source Medicare data for Francis Patrick Matuszak, DO (NPI 1447755830), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Francis Patrick Matuszak, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Francis Patrick Matuszak, DO?

Francis Patrick Matuszak, DO is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Francis Patrick Matuszak, DO have Open Payments data?

Francis Patrick Matuszak, DO has 100 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.